Delisting risk
DYAI · NASDAQ · Biotechnology

Dyadic International (DYAI)

Produces proteins and enzymes through C1 and Dapibus platforms for life sciences, food, and bio-industrial uses.

$0.5470
Pre-market+0.02 (+3.05%)
At close$0.5308(−0.24%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue010021001011
Cost of revenue000000010011
Gross profit000020001000
232222223122
Research & development111101010000
122211211122
General & administrative122211211122
Other expenses000000001000
Operating income−2−2−2−20−2−2−2−2−2−2−2
0−20000000000
Interest income000000000000
Interest expense000000000000
Other non-operating income000000000000
Income before tax−2−4−2−20−2−2−2−2−2−2−2
Income tax expense0−20000000000
Net income from continuing operations−2−2−2−20−2−2−2−2−2−2−2
Net income−2−2−2−20−2−2−2−2−2−2−2
EPS, basic−$0.06−$0.07−$0.07−$0.07−$0.01−$0.05−$0.07−$0.06−$0.06−$0.04−$0.05−$0.06
EPS, diluted−$0.06−$0.07−$0.07−$0.07−$0.01−$0.05−$0.07−$0.06−$0.06−$0.04−$0.05−$0.06
Weighted average shares, basic292929293029303035333636
Weighted average shares, diluted292929293029303035333636
EBITDA−2−1−2−20−1−2−2−2−1−2−2
Depreciation & amortization020000000000
EBIT−2−2−2−20−1−2−2−2−1−2−2